Biopharmaceutical
Pharmaceutical
Cancer Prevention

Pieris Pharmaceuticals

$3.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (1.61%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell PIRS and other stocks, options, ETFs, and crypto commission-free!

About

Pieris Pharmaceuticals, Inc. Common Stock, also called Pieris Pharmaceuticals, is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Read More Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Employees
107
Headquarters
Boston, Massachusetts
Founded
2001
Market Cap
167.87M
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
488.61K
High Today
$3.17
Low Today
$3.08
Open Price
$3.11
Volume
138.68K
52 Week High
$7.42
52 Week Low
$2.39

Collections

Biopharmaceutical
Pharmaceutical
Cancer Prevention
Medical
Biotechnology
Technology
Health
2015 IPO

News

Simply Wall StMar 14

Is Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) A Volatile Stock?

If you own shares in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. First, we have company specific volatility, which is the price gyrations of an individual stock. Holding at least 8 stocks can reduce this kind of risk across a portfolio. The other type, w...

115
Yahoo FinanceFeb 26

Factors of Influence in 2019, Key Indicators and Opportunity within Conagra Brands, Pieris Pharmaceuticals, ArQule, MoneyGram International, Internap, and TIM Participacoes S.A β€” New Research Emphasiz

NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Conagra Brands Inc. (CAG), Pieris Pharmaceuticals, Inc. (PIRS), ArQule, Inc. (ARQL), MoneyGram International Inc. (MGI), Internap Corporation (INAP), and TIM Participacoes S.A. (TSU), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst ...

64
MarketBeatFeb 25

Stock Price, News, & Analysis for Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is involved in developing PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases; PRS-332, a bispecific anti...

24

Earnings

-$0.23
-$0.09
$0.04
$0.18
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.15 per share
Actual
-$0.21 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.